ADVA
26.4.2022 09:02:06 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Schleswig-Holstein Netz, one of northern Germany’s largest power grid operators, has successfully completed a field trial of quantum-secured data transport using the ADVA FSP 3000 platform with ConnectGuard™ Layer 1 encryption technology. For the first time with a full commercial solution, a future-proof key exchange based on quantum key distribution (QKD) was used to encrypt data across overhead fiber cables. Until now, ensuring QKD performance in the harsh outdoor conditions of aerial fiber was thought to be a major barrier. The trial shows how mission-critical utility networks can now counter the urgent threat of attacks from quantum computers. Technology from ADVA’s partner, the quantum cryptography company ID Quantique, also played a significant role generating QKD keys.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005727/en/
“The emergence of large quantum computers will jeopardize mission-critical networks like never before. That’s why we’re taking action now and trialing technology to safeguard power infrastructure for the long term. The success of our PoC with ADVA’s secure solution is a key breakthrough for protecting utility networks with QKD,” said Benjamin Merkt, CTO of Schleswig-Holstein Netz. “We’ve shown that grids like ours that use aerial fiber stretching across hundreds of kilometers can be protected against quantum-enabled hacking, even in adverse climactic conditions. It’s a major step towards guaranteeing the integrity and security of critical data in transit both today and in the post-quantum world.”
QKD offers a way to secure sensitive data transport against all forms of cyberattack, including from quantum computers that could render traditional public key cryptography useless. Distributing encryption keys in a quantum state ensures that any attempt to intercept traffic disturbs photons, introducing coding errors and alerting operators. But implementing the technology in power infrastructure is challenging as most utility communication networks are integrated with long-distance high-voltage overhead lines. As QKD performance can be easily affected by environmental factors, stability was a key criterion in Schleswig-Holstein Netz’s trial, but the configuration proved to be stable and suitable for aerial fiber. The success of ADVA’s solution shows a way forward for quantum-secure utility networks.
“This PoC proves that QKD-based encryption is achievable in network architectures like this. Even with fiber optics integrated with 110kV overhead lines and unprotected from wind, solar radiation and thunderstorms, our solution was successful,” commented Helmut Griesser, director of advanced technology at ADVA. “Working closely with Schleswig-Holstein Netz and our partner ID Quantique, we’ve been able to demonstrate that QKD has a major role in safeguarding utilities. We’ve shown that our FSP 3000 ConnectGuard™ encryption has the power to protect our most sensitive and vital assets from cybercriminals even in the age of quantum computers.”
The PoC was performed as part of the OPENQKD project , which is supported by the European Union’s Horizon 2020 research and innovation program. The project creates several testbeds and demonstrates numerous use cases, laying the foundations of a pan-European quantum network.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About ID Quantique
Founded in 2001 as a spin-off of the Group of Applied Physics of the University of Geneva, ID Quantique is the world leader in quantum-safe crypto solutions, designed to protect data for the future. The company provides quantum-safe network encryption, secure quantum key generation and Quantum Key Distribution solutions and services to the financial industry, enterprises and government organizations globally. IDQ’s quantum random number generator has been validated according to global standards and independent agencies, and is the reference in highly regulated and mission critical industries – such as security, encryption, critical infrastructure and IoT – where trust is paramount. For more information, please visit www.idquantique.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005727/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
